Allarity Therapeutics Management

Management criteria checks 1/4

Allarity Therapeutics' CEO is Thomas Jensen, appointed in Jan 2004, has a tenure of 20.83 years. directly owns 0% of the company’s shares, worth $3.97. The average tenure of the management team and the board of directors is 0.2 years and 2.1 years respectively.

Key information

Thomas Jensen

Chief executive officer

US$24.7k

Total compensation

CEO salary percentage	n/a
CEO tenure	20.8yrs
CEO ownership	0.00007%
Management average tenure	less than a year
Board average tenure	2.1yrs

Recent management updates

Recent updates

CEO

Thomas Jensen (46 yo)

20.8yrs

Tenure

US$24,720

Compensation

Mr. Thomas H. Jensen is Co-Founder of Allarity Therapeutics, Inc. and serves as its Director since July 7, 2022. He is Chief Executive Officer since December 08, 2023 at Allarity Therapeutics, Inc. and ser...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Thomas Jensen	Founder	20.8yrs	US$24.72k	0.000070% $ 4.0
Steen Knudsen	Founder & Chief Scientific Officer	20.8yrs	US$266.22k	0.000070% $ 4.0
Jeremy Graff	President & Chief Development Officer	less than a year	no data	no data
Peter Jensen	Co-Founder	no data	US$128.02k	no data
Alexander Epshinsky	Chief Financial Officer	less than a year	no data	no data
Jose Iglesias	Consultant Chief Medical Officer	less than a year	no data	no data

0.2yrs

Average Tenure

58.5yo

Average Age

Experienced Management: ALLR's management team is not considered experienced ( 0.2 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Jensen	Founder	2.3yrs	US$24.72k	0.000070% $ 4.0
Daniel Von Hoff	Member of Scientific Advisory Board	no data	no data	no data
Gerald McLaughlin	Independent Chairman of the Board	2.1yrs	US$107.38k	0.000070% $ 4.0
Joyce O'Shaughnessy	Member of Scientific Advisory Board	no data	no data	no data
Mansoor Mirza	Member of Scientific Advisory Board	no data	no data	no data
Joseph Vazzano	Independent Director	1.3yrs	US$29.17k	no data
Laura Benjamin	Independent Director	1.3yrs	US$27.71k	no data
Ursula Matulonis	Member of Scientific Advisory Board	no data	no data	no data
Roberto Pili	Member of Scientific Advisory Board	2.4yrs	no data	no data

2.1yrs

Average Tenure

57yo

Average Age

Experienced Board: ALLR's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Allarity Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Allarity Therapeutics, Inc. Announces Management Appointments

Allarity Therapeutics, Inc. Appoints Alex Epshinsky as Chief Financial Officer

Allarity Therapeutics, Inc., Annual General Meeting, Jul 26, 2024

Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board

Allarity Therapeutics Announces Executive Changes

Allarity Therapeutics, Inc. Announces Board Changes

Recent updates

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics, Inc. Announces Management Appointments

Holzer & Holzer, LLC Announces Class Action Lawsuit on Behalf of Allarity Therapeutics, Inc

Allarity Therapeutics, Inc. Appoints Alex Epshinsky as Chief Financial Officer

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

Allarity Therapeutics Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Allarity Therapeutics, Inc., Annual General Meeting, Jul 26, 2024

Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial

Allarity Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million.

Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Allarity Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $0.947 million.

Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding

Allarity Therapeutics, Inc. announced that it has received $0.8 million in funding from 3i, LP

Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board

Allarity Therapeutics Announces Executive Changes

Allarity Therapeutics, Inc. Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic

Allarity Therapeutics, Inc. Receives A Letter from Nasdaq Listing Qualifications Staff

Allarity Therapeutics Receives Notification from the Nasdaq Listing Qualifications Staff Regarding Non-Compliance with Listing Rule 5550(a)(2)

Allarity Therapeutics Announces Positive Early Data from an Ongoing Clinical Trial, and External Partnering for Its DRP Technology

Allarity Therapeutics, Inc. Announces the Publication of its Clinical Validation of a Novel Drug-Specific DRP-Companion Diagnostic (CDx) for Dovitinib in the Peer-Reviewed Journal PLOS ONE

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics, Inc. and Detsamma Investments Pty. Ltd. Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics

Allarity Therapeutics, Inc. Provides Nasdaq Compliance Update

Allarity Therapeutics, Inc. Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Allarity Therapeutics, Inc. Announces Initial Results from Its European Phase 2 Clinical Trial Evaluating the Efficacy of Ixempra®? in Metastatic Breast Cancer Patients

Allarity Therapeutics, Inc. announced that it expects to receive $0.35 million in funding from 3i, LP

Allarity Therapeutics Announces Reverse Stock Split of Common Stock to Bring it into Compliance with Nasdaq’s Listing Requirement Regarding Minimum Share Price

Allarity Therapeutics, Inc. Announces Results of Prospective Phase 2 Clinical Study

Allarity Therapeutics Announces Update on Delisting from The Nasdaq Stock Market

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Market Value of Publicly Held Shares

High number of new and inexperienced directors

Allarity Therapeutics Receives Notice from the Nasdaq

Allarity Therapeutics Regains Compliance with NASDAQ Listing Requirements

Allarity Therapeutics GAAP EPS of -$0.72 misses by $0.46

Allarity Therapeutics, Inc. Announces the Appointment of Jerry Mclaughlin as a Member of its Board of Directors, Effective October 1, 2022

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics GAAP EPS of -$0.52 misses by $0.07

Allarity Therapeutics, Inc., Annual General Meeting, Nov 04, 2022

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics Announces Appointment of New Members to Its Board of Directors

Allarity Therapeutics, Inc. Announces Executive Leadership Transition

Allarity Therapeutics appoints interim CEO, CFO

Allarity Therapeutics, Inc. Appoints Roberto Pili as Member of the Company’s Scientific Advisory Board

Allarity Therapeutics, Inc. Announces Impairment for the First Quarter Ended March 31, 2022

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics, Inc. announced delayed annual 10-K filing

Allarity Therapeutics, Inc. Receives Refusal to File Letters from U.S. FDA

Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age